Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant decline in short interest in May. As of May 29th, there was short interest totaling 8,663 shares, a decline of 82.5% from the May 14th total of 49,381 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 403,780 shares, the short-interest ratio is presently 0.0 days.

Fresenius SE & Co. Price Performance

OTCMKTS FSNUY opened at $10.83 on Wednesday. The firm’s fifty day simple moving average is $11.93 and its two-hundred day simple moving average is $13.38. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.41. Fresenius SE & Co. has a 12-month low of $10.33 and a 12-month high of $33.93. The firm has a market capitalization of $24.40 billion, a P/E ratio of 14.44 and a beta of 0.64.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%.The firm had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Analysts forecast that Fresenius SE & Co. will post 1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.